ASSEMBLY BIOSCIENCES INC
Pagina dedicata companiei ASSEMBLY BIOSCIENCES INC listata cu simbolurile US.ASMB, US.ASMBc
Descriere companieModificare
Assembly Biosciences, Inc. (www.assemblybio.com) is a clinical-stage biotechnology company advancing a class of oral therapeutic candidates for the treatment of chronic hepatitis B virus (HBV) infection. The Company’s inhibitor product candidates include Vebicorvir (VBR), ABI-H2158 (2158), and ABI-H3733 (3733). Vebicorvir (VBR) is licensed from Indiana University and treating patients with VBR plus nucelos(t)ide analog reverse transcriptase inhibitors (NrtIs) and ultimately transitioning patients. ABI-H2158 (2158) is chemically distinct from VBR. ABI-H3733 (3733) for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan and Macau (the Territory). The Company’s research and development programs pursuing multiple drug candidates that inhibit the HBV replication cycle and block the generation of covalently closed circular DNA (cccDNA), to discover and develop finite and curative therapies for patients with HBV.
Grafic actiuni companieModificare